• Quinn, Joseph (PI)
  • Growdon, John (PI)
  • Sperling, Reisa A. (PI)
  • Brewer, James (PI)
  • Peskind, Elaine R. (PI)
  • Baker, Laura D. (PI)
  • Hill, Robert (PI)
  • Raman, Rema (PI)
  • Rissman, Robert (PI)
  • Bell, Karen (PI)
  • Thal, Leon (PI)
  • Relkin, Norman R. (PI)
  • Galasko, Douglas (PI)
  • Salmon, David (PI)
  • Grundman, Michael (PI)
  • Singer, Clifford (PI)
  • Ferris, Steven (PI)
  • Tariot, Pierre N. (PI)
  • Aisen, Paul (PI)
  • Sano, Mary (PI)
  • Thomas, Ronald G. (PI)
  • Rafii, Michael (PI)
  • Mobley, William (PI)

Project: Research project

Project Details


The enclosed application represents the development of a consortium of
investigators who will carry out multicenter drug trials in Alzheimer's
disease (AD). This consortium, containing 30 Alzheimer Disease Study Units
(ADSUs), will critically examine existing instruments for the evaluation of
AD patients participating in clinical drug trials. When appropriate, new
instruments will be developed for use by this group. Specific drug trials
proposed are a pilot study to examine the safety of nerve growth factor
administered to a small number of AD patients. If safe, a multicenter
double-blind, parallel, placebo-controlled trial examining both short- and
long-term administration of nerve growth factor in 150 subjects is
proposed. A second study examining the ability of deprenyl, a selective
monoamine oxidase-B inhibitor, to slow the rate of decline in AD is also
proposed. The second study will be a two-year, parallel, double-blind,
placebo-controlled trial in 300 subjects. Additional drug trials are
proposed for Years 4 and 5 of this grant. The specific drug trials
included in this proposal are examples of trials that might be carried out
by this consortium. Final decisions regarding which drugs are tested will
be made in consultation with NIA and the NIA-appointed Oversight Committee.
Effective start/end date9/30/912/28/18


  • National Institutes of Health


  • Medicine(all)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.